Xiao Hui Gu
No más puestos en curso
Historial de carrera de Xiao Hui Gu
Antiguos cargos conocidos de Xiao Hui Gu.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01/01/2008 | 01/01/2008 |
| EXELIXIS, INC. | Corporate Officer/Principal | - | - |
| PHARMARON BEIJING CO., LTD. | Corporate Officer/Principal | 01/05/2011 | - |
Formación de Xiao Hui Gu.
| Hunan Normal University | Undergraduate Degree |
| Shanghai Institute of Organic Chemistry | Doctorate Degree |
Estadísticas
Internacional
| China | 4 |
| Estados Unidos | 3 |
Operativa
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorial
| Commercial Services | 3 |
| Consumer Services | 3 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| PHARMARON BEIJING CO., LTD. | Commercial Services |
| EXELIXIS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Bolsa de valores
- Insiders
- Xiao Hui Gu
- Experiencia